Horizon 1 1 17 ACLN : Articles dans des revues avec comité de lecture non répertoriées par l'AERES Phytotherapy Research 193-197 LEISHMANIOSE TRYPANOSOMIASE HUMAINE TRAITEMENT MEDICAL EFFICACITE ANIMAL DE LABORATOIRE CHAMPIGNON EXTRACTION ETUDE EXPERIMENTALE ETUDE COMPARATIVE SESQUITERPENE DITERPENE PARAGUAY 1997 fdi:010010459 ENG Phytotherapy Research 0951-418X 10.1002/(SICI)1099-1573(199705)11:3<193::AID-PTR68>3.0.CO;2-R https://www.documentation.ird.fr/hor/fdi:010010459 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_47-48/010010459.pdf 11 Horizon (IRD) Seventeen extracts and seven secondary metabolites isolated from basidiomycetes were tested in medium culture against promastigote forms of #Leishmania$ spp. and bloodstream forms of #Trypanosoma cruzi$. Extracts from the culture filtrate or mycelium were generally inactive against the parasites except the #Zucoagaricus$ genus mycelium extract which reduced by 47% the number of bloodstream forms. Striatin A, striatin B and podoscyphic acid exhibited in vitro activity at 10,5 and 100 micrograms/mL, respectively. One compound showed activity against bloodstream forms of #T. cruzi$, the sesquiterpenoid naematolin, lysing the parasites by 79%. BALB/c mice infected with #L. amazonensis$ were treated three weeks post-infection with striatin A and striatin B by subcutaneous route for 15 days at 10 mg/kg daily. The reference drug, N-methylglucamine antimonate, administered by subcutaneous injections at 28 mg Sbv/kg/day for 15 days reduced the parasite burden by 71,2% (p<0,05). Subcutaneous administration of striatin A at 10 mg/kg produced a weak decrease of the parasite burdens in the footpad by 17,6%. The treatment with striatin B had no effect and showed higher toxicity than striatin A. (Résumé d'auteur) 052PHLEIS03 ; 052GLOTRY03 ; 076PLAMED03